Research team Katja Pokrovskaja Tamm

Novel targeted therapies in cancer to overcome drug resistance

Projects

Autophagy in anti-cancer therapy
Molecular mechanisms underlying pediatric leukemia development and treatment
STAT3 as a target in anti-cancer therapy

Funding

  • Swedish Cancer Society (Mechanisms of action of anti-cancer drugs and therapy resistance, STAT3 in cancer and therapy resistance)
  • The Swedish Childhood Cancer Foundation (Molecular mechanisms underlying pediatric leukemia development and treatment)
  • Swedish foundation for Strategic Research (Autophagy in anti-cancer therapy)
  • The Cancer Society in Stockholm (Drug development to overcome drug resistance and the Role of non-coding RNA in cancer, STAT3 activation in cancer and therapy resistance)
  • Karolinska Institutet, KID (STAT3 as a target for anti-cancer therapy)

Group members

Katja Pokrovskaja Tamm, PI, PhD, Associate Professor
Yasmin Yu, MSc, PhD student
Aishwarya Konnur, Master student

Affiliated

Angelo de Milito, Associate Professor, Sprint Bioscience, Huddinge
Santiago Parpal, Researcher, Sprint Bioscience, Huddinge

Selected publications

Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death.
Busker S, Qian W, Haraldsson M, Espinosa B, Johansson L, Attarha S, et al
Sci Adv 2020 03;6(12):eaax7945

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.
Vidarsdottir L, Fernandes RV, Zachariadis V, Das I, Edsbäcker E, Sigvaldadottir I, et al
Melanoma Res. 2020 Oct;30(5):443-454

STAT3 is activated in multicellular spheroids of colon carcinoma cells and mediates expression of IRF9 and interferon stimulated genes.
Edsbäcker E, Serviss JT, Kolosenko I, Palm-Apergi C, De Milito A, Tamm KP
Sci Rep 2019 Jan;9(1):536

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
Dyczynski M, Yu Y, Otrocka M, Parpal S, Braga T, Henley AB, et al
Cancer Lett. 2018 10;435():32-43

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment.
Dyczynski M, Vesterlund M, Björklund AC, Zachariadis V, Janssen J, Gallart-Ayala H, et al
Cell Death Dis 2018 08;9(9):846

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, et al
PLoS ONE 2017 ;12(6):e0178844

Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs.
Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates EG, et al
Int. J. Cancer 2015 Feb;136(4):E51-61

An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H, Kolosenko I, Björklund AC, Protsyuk D, Österborg A, Grandér D, et al
Exp. Cell Res. 2013 Mar;319(5):600-11

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.
Buentke E, Nordström A, Lin H, Björklund AC, Laane E, Harada M, et al
Blood Cancer J 2011 Jul;1(7):e31

Activation of STAT1 is required for interferon-alpha-mediated cell death.
Arulampalam V, Kolosenko I, Hjortsberg L, Björklund AC, Grandér D, Tamm KP
Exp. Cell Res. 2011 Jan;317(1):9-19

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy.
Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Khahariza P, et al
Cell Death Differ. 2009 Jul;16(7):1018-29

18-02-2022